Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
Functional supersensitivity of mesolimbic and striatal dopamine receptors has been suggested to contribute to the pathogenesis of schizophrenia and tardive dyskinesia. Using the rodent model of chronic administration of the neuroleptic haloperidol, we investigated the possible desensitizing effects of a tripeptide structurally unrelated to dopamine agonists, L-prolyl-L-leucyl-glycinamide (PLG) on mesolimbic and striatal dopaminergic receptor supersensitivity. Administration of PLG either prior to or after chronic haloperidol, inhibited the supersensitivity of dopamine receptors. The results have implications for pharmacological intervention in preventing tardive dyskinesia and relapse psychosis of schizophrenia.
Chiu
P
P
Rajakumar
G
G
Chiu
S
S
Johnson
R L
RL
Mishra
R K
RK
D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology; D007700:Kinetics; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism*; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism
D011954:Receptors, Dopamine; D013134:Spiperone; D009075:MSH Release-Inhibiting Hormone; D006220:Haloperidol